Show simple item record

dc.contributor.authorSilva, Leia C. R.
dc.contributor.authorOrtigosa, Luciena C. M.
dc.contributor.authorBenard, Gil
dc.date.accessioned2024-10-21T18:45:52Z
dc.date.available2024-10-21T18:45:52Z
dc.date.issued2010
dc.identifier.citationImmunotherapy
dc.identifier.issn1750-7448
dc.identifier.urihttp://dx.doi.org/10.2217/IMT.10.67
dc.identifier.urihttps://repositorio.maua.br/handle/MAUA/1488
dc.description.abstractTNF-alpha is a potent inducer of the inflammatory response, a key regulator of innate immunity and plays an important role in the regulation of Th1 immune responses against intracellular bacteria and certain viral infections. However, dysregulated TNF can also contribute to numerous pathological situations. These include immune-mediated inflammatory diseases (IMIDs) including rheumatoid arthritis, Crohn's disease, psoriatic arthritis, ankylosing spondylitis, ulcerative colitis and severe chronic plaque psoriasis. Animal and human studies concerning the role of TNF-alpha in IMIDs have led to the development of a therapy based on TNF blockage. This article focuses first on the potential mechanisms by which the three currently licensed agents, adalimumab, etarnecept and infliximab, decrease the inflammatory activity of patients with different IMIDs. Second, it focuses on the risks, precautions and complications of the use of TNF-alpha inhibitors in these patients.en
dc.format.extent17.0
dc.languageInglêspt_BR
dc.publisherFUTURE MEDICINE LTDen
dc.relation.ispartofIMMUNOTHERAPY
dc.rightsAcesso Restrito
dc.sourceWeb of Scienceen
dc.subjectadalimumaben
dc.subjectetanercepten
dc.subjectimmune-mediated inflammatory diseasesen
dc.subjectinfliximaben
dc.subjectsoluble TNFen
dc.subjectTNF-alphaen
dc.subjecttransmembrane TNFen
dc.subjectTUMOR-NECROSIS-FACTORen
dc.subjectINFLIXIMAB INDUCES APOPTOSISen
dc.subjectPATIENT RECEIVING INFLIXIMABen
dc.subjectRANDOMIZED CONTROLLED-TRIALSen
dc.subjectCASPASE-DEPENDENT PATHWAYen
dc.subjectSOCIETY-FOR-RHEUMATOLOGYen
dc.subjectLONG-TERM TREATMENTen
dc.subjectLUPUS-LIKE SYNDROMEen
dc.subjectREGULATORY T-CELLSen
dc.subjectCROHNS-DISEASEen
dc.subjectImmunologyen
dc.subject.otheradalimumaben
dc.subject.otheretanercepten
dc.subject.otherimmune-mediated inflammatory diseasesen
dc.subject.otherinfliximaben
dc.subject.othersoluble TNFen
dc.subject.otherTNF-alphaen
dc.subject.othertransmembrane TNFen
dc.subject.otherTUMOR-NECROSIS-FACTORen
dc.subject.otherINFLIXIMAB INDUCES APOPTOSISen
dc.subject.otherPATIENT RECEIVING INFLIXIMABen
dc.subject.otherRANDOMIZED CONTROLLED-TRIALSen
dc.subject.otherCASPASE-DEPENDENT PATHWAYen
dc.subject.otherSOCIETY-FOR-RHEUMATOLOGYen
dc.subject.otherLONG-TERM TREATMENTen
dc.subject.otherLUPUS-LIKE SYNDROMEen
dc.subject.otherREGULATORY T-CELLSen
dc.subject.otherCROHNS-DISEASEen
dc.subject.otherImmunologyen
dc.titleAnti-TNF-? agents in the treatment of immune-mediated inflammatory diseases: mechanisms of action and pitfallsen
dc.typeArtigo de Periódicopt_BR
dc.identifier.doi10.2217/IMT.10.67
dc.description.affiliationInstituto Maua de Tecnologia
dc.description.affiliationUniversidade de Sao Paulo
dc.identifier.wosWOS:000285705300011
dc.citation.issue6
dc.citation.epage833
dc.citation.spage817
dc.citation.volume2


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record